Umoja is a pioneer in the strategically important in vivo CAR T-cell therapy space and is working on a program in multiple myeloma. The company’s in vivo gene delivery technology, enables a patient’s own immune system to combat disease by allowing chimeric antigen receptor (CAR) payloads to be delivered directly to T cells via a lentiviral vector in a single, mass-producible injection. Umoja’s platform represents unique off-the-shelf solutions bypassing the traditional complexities of CAR-T therapies.